Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans.
J Med Econ
; 26(1): 422-429, 2023.
Article
in En
| MEDLINE
| ID: mdl-36924214
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cardiovascular Diseases
/
Substance-Related Disorders
/
Depressive Disorder, Major
/
Depressive Disorder, Treatment-Resistant
Type of study:
Guideline
/
Health_economic_evaluation
/
Observational_studies
Aspects:
Implementation_research
Limits:
Adult
/
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
J Med Econ
Journal subject:
SERVICOS DE SAUDE
Year:
2023
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom